Abstract
Background: Desmoid fibromatosis (DF) is a pathological intermediate fibroblastoma that is difficult to control locally due to its invasive nature, especially in the extremities. Although anlotinib demonstrated efficacy in treating DF with tolerable safety, the impact of surgical intervention in conjunction with anlotinib administration on local control in patients with extremity DF remains undetermined. Methods: We conducted a retrospective examination of clinical documentation for patients with resectable DF of the extremities treated with surgery between January 2010 and June 2022. Patients were divided into two cohorts: surgery alone and surgery combined with anlotinib. Results: In total, 48 consecutive patients were included. The 3-year recurrence-free survival (RFS) of the surgery alone cohort and the surgery plus anlotinib cohort were 37.7% and 72.6%, respectively (p = 0.022). Conclusion: Surgery combined with anlotinib appears to be effective in controlling local recurrence in patients with resectable DF of the extremities, with an acceptable safety profile.
Introduction
Desmoid fibromatosis (DF) is a locally aggressive tumor that, while non-metastatic, is notoriously difficult to manage due to its infiltrative growth pattern. In the extremities, these tumors often wrap around critical nerves and blood vessels. Historically, wide surgical resection was the primary treatment, but recurrence rates remain high—up to 77% in some reports. This has led to a shift toward active surveillance and systemic therapies. Anlotinib, a multi-targeted tyrosine kinase inhibitor (TKI), has shown efficacy in unresectable DF. This study investigates whether combining surgery with anlotinib can improve local control for resectable cases.
Methods
Researchers conducted a retrospective study of 48 patients at West China Hospital. The patients were categorized into two groups:
- Surgery Alone (n=25): Patients treated before the hospital adopted the anlotinib protocol in 2018.
- Surgery + Anlotinib (n=23): Patients treated after 2018 who received perioperative anlotinib (8 mg/day, 2 weeks on/1 week off).
The study also allowed for "crossover," where patients in the surgery-only group who suffered a recurrence could move into the combination therapy group for subsequent treatment. Outcomes were measured using Recurrence-Free Survival (RFS), pain levels (VAS score), and limb function (MSTS score).
Key Results
Improved Local Control
The addition of anlotinib significantly improved local control. The 3-year RFS for the combination group was 72.6%, compared to 37.7% for the surgery-alone group ($p = 0.022$). This suggests that anlotinib may act as an effective adjuvant, targeting microscopic disease that surgery alone might miss.
Functional Outcomes and Pain Relief
Beyond tumor control, the combination therapy yielded better quality-of-life outcomes. At the final follow-up, the median pain (VAS) score was significantly lower in the combination group (2 vs. 5). Functional outcomes were also superior, with a median MSTS score of 27 for the combo group versus 19 for surgery alone. This indicates that adjuvant anlotinib may allow for less aggressive surgery while maintaining better local control.
Safety Profile
The safety of the 8 mg/day anlotinib dose was manageable. While approximately half of the patients experienced hand-foot-skin syndrome, most adverse events were mild (Grade 1 or 2). Only two patients experienced Grade 3 events, and none required drug discontinuation due to toxicity.
Discussion and Conclusion
This retrospective study suggests that surgery combined with anlotinib is a potent strategy for managing resectable extremity DF. The combination nearly doubled the 3-year RFS and significantly improved functional outcomes compared to surgery alone.
Limitations include the study's retrospective nature and small sample size. Because DF can recur many years later, longer follow-up is necessary to determine if these benefits are permanent. The authors conclude that prospective, multi-center randomized controlled trials are needed to validate these findings and standardize treatment protocols for this challenging disease.
Summary updated